As this is an inflammatory adipose tissue disorder, it is hypothesized that this effect is mediated by the reduction in systemic and tissue inflammation that GLP-1 drugs have been shown to cause in other inflammatory and chronic diseases, such as fatty liver disease and inflammatory bowel disease [30,31,32,33,34]. Here, GLP1R is linked to inflammatory bowel disease.